Kadoaki Oohashi

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. ErbB Receptors 87%
3. Lung Neoplasms 65%
4. Mutation 54%
5. Protein-Tyrosine Kinases 41%
6. Gefitinib 36%
7. Adenocarcinoma of Lung 29%
8. osimertinib 27%
9. Neoplasms 26%
10. Lung 23%
11. Anaplastic Lymphoma Kinase 22%
12. CH5424802 19%
13. Crizotinib 15%
14. Exons 15%
15. Afatinib 14%
16. Ado-Trastuzumab Emtansine 13%
17. Bevacizumab 13%
18. N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine 13%
19. Therapeutics 12%
20. capmatinib 11%
21. Safety 11%
22. Transgenic Mice 10%
23. Erlotinib Hydrochloride 10%
24. Progression-Free Survival 10%
25. Cell Line 10%
26. Survival 9%
27. Drug Therapy 9%
28. Bronchoscopy 9%
29. Chemoradiotherapy 8%
30. Gene Fusion 8%
31. Prospective Studies 8%
32. Japan 7%
33. Cetuximab 7%
34. Cisplatin 7%
35. mouse EGFR protein 7%
36. Carboplatin 7%
37. Immunoglobulin G4-Related Disease 6%
38. Carcinogenesis 6%
39. Oncogenes 6%
40. Confidence Intervals 6%
41. Lymph Nodes 6%
42. Furosemide 6%
43. Biopsy 6%
44. Mannitol 6%
45. Midazolam 6%
46. Gene Dosage 6%
47. Immunohistochemistry 6%
48. Vascular Endothelial Growth Factor Receptor-2 6%
49. Fentanyl 6%
50. naquotinib 6%